vTv Therapeutics Financials - Benzinga

vTv Therapeutics Inc

VTVTNASDAQ

Trade with Public

Trade with Public

$33.35

-0.12-0.36%

At close: Sep 4, 5:00 PM EST

$33.47

0.120.36%

After Hours: Sep 4, 6:16 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

vTv Therapeutics Financials

vTv Therapeutics (VTVT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of $(0.92) per share

Benzinga Newsdesk

PRO
vTv Therapeutics Q1 EPS $1.65 Beats $(0.10) Estimate, Sales $36.839M Beat $20.000M Estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $(0.10) by 1933.33 percent. This is a 314.29 percent increase over losses of $(0.77) per share

Benzinga Newsdesk

PRO
vTv Therapeutics Q4 EPS $(0.58) Beats $(1.17) Estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(1.17) by 50.21 percent. This is a 5.45 percent decrease over losses of $(0.55) per share from

Benzinga Newsdesk

PRO
vTv Therapeutics Q3 EPS $(1.08) Misses $(0.98) Estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.98) by 10.2 percent. This is a 22.73 percent decrease over losses of $(0.88) per share from

Benzinga Newsdesk

PRO
vTv Therapeutics Q2 EPS $(0.92) Misses $(0.82) Estimate.

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.82) by 11.52 percent. This is a 13.58 percent decrease over losses of $(0.81) per share

Benzinga Newsdesk

PRO
vTv Therapeutics Q1 EPS $(0.77) Beats $(0.92) Estimate

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.92) by 16.3 percent. This is a 34.19 percent increase over losses of $(1.17) per share from

Benzinga Newsdesk